Oxaliplatin injection Clinical Trials

4 actively recruiting trials

No change since May 2026

Also known as: NSC 266046, Oxaliplatin

Pipeline

Phase 2: 1Phase 3: 3

Top Sponsors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
Nanjing Leads Biolabs Co.,Ltd1
Fujian Cancer Hospital1
BeBetter Med Inc1

Indications

Cancer4
Advanced Solid Tumour1
Relapsed/Refractory Diffuse Large B-cell Lymphoma1
Diffuse Large B-Cell Lymphoma1
Gastric Cancer1

Other4 trials

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Phase 3

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Phase 2

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.